A phase i study of temsirolimus and thoracic radiation in non-small-cell lung cancer

Clinical Lung Cancer

Volumn 15, Issue 2, 2014, Pages 119-123

  Waqar, Saiama N ^a   Robinson, Clifford ^a   Bradley, Jeffrey ^a   Goodgame, Boone ^b   Rooney, Melissa ^a   Williams, Kristina ^a   Gao, Feng ^a   Govindan, Ramaswamy ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Non small cell lung cancer; Radiation; Temsirolimus

Indexed keywords

ANTINEOPLASTIC AGENT; RAPAMYCIN; TEMSIROLIMUS;

ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROGNOSIS; RADIATION DOSE; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; SIROLIMUS; SURVIVAL RATE;

EID: 84894101093     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.11.007     Document Type: Article

References (28)

1. D. Morgensztern, B. Goodgame, and M.Q. Baggstrom et al. The effect of FDG-PET on the stage distribution of non-small cell lung cancer J Thorac Oncol 3 2008 135 139
2. D.R. Gandara, K. Chansky, and K.S. Albain et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504 J Clin Oncol 21 2003 2004 2010
3. N. Hanna, M. Neubauer, and C. Yiannoutsos et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology J Clin Oncol 26 2008 5755 5760
4. S.I. Jalal, H.D. Riggs, and A. Melnyk et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology Ann Oncol 23 2012 1730 1738
5. R.O. Dillman, S.L. Seagren, and K.J. Propert et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer N Engl J Med 323 1990 940 945
6. J.D. Bradley, R. Paulus, and R. Komaki et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: results on radiation dose in RTOG 0617 ASCO Meeting Abstracts 31 2013 7501
7. E. Vokes, L. Wang, and J. Vansteenkiste et al. Preliminary safety and treatment delivery data during concurrent phase of chemoradiation therapy of the PROCLAIM trial: a phase 3 trial of pemetrexed, cisplatin, and radiotherapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiotherapy followed by consolidation cytotoxic chemotherapy of choice in patients with stage III nonsquamous cell lung cancer J Thorac Oncol 8 2013 S551 S552
8. K. Kelly, K. Chansky, and L.E. Gaspar et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 2008 2450 2456
9. D.R. Spigel, J.D. Hainsworth, and D.A. Yardley et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab J Clin Oncol 28 2010 43 48
10. T. Schmelzle, and M.N. Hall TOR, a central controller of cell growth Cell 103 2000 253 262
11. M. Wislez, M.L. Spencer, and J.G. Izzo et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras Cancer Res 65 2005 3226 3235
12. C.C. Hudson, M. Liu, and G.G. Chiang et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin Mol Cell Biol 22 2002 7004 7014
13. G. Hudes, M. Carducci, and P. Tomczak et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
14. M.B. Atkins, M. Hidalgo, and W.M. Stadler et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 2004 909 918
15. T. Reungwetwattana, J.R. Molina, and S.J. Mandrekar et al. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study J Thorac Oncol 7 2012 919 922
16. X. Zhang, T. Kon, and H. Wang et al. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha Cancer Res 64 2004 8139 8142
17. N.D. Arvold, N. Guha, and D. Wang et al. Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro Int J Radiat Oncol Biol Phys 62 2005 207 212
18. K.J. Williams, B.A. Telfer, and D. Xenaki et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1 Radiother Oncol 75 2005 89 98
19. Y.M. Kirova, C. Chargari, and M. Amessis et al. Concurrent involved field radiation therapy and temsirolimus in refractory mantle cell lymphoma (MCL) Am J Hematol 85 2010 892
20. J.N. Sarkaria, E. Galanis, and W. Wu et al. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks Clin Cancer Res 16 2010 5573 5580
21. M.G. Kris, B.E. Johnson, and D.J. Kwiatkowski et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC) ASCO Meeting Abstracts 29 2011 CRA7506
22. S. Niho, Y. Ohe, and S. Ishikura et al. Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402) Ann Oncol 23 2012 2253 2258
23. R. Govindan, J. Bogart, and E.E. Vokes Locally advanced non-small cell lung cancer: the past, present, and future J Thorac Oncol 3 2008 917 928
24. G. Iyer, A.J. Hanrahan, and M.I. Milowsky et al. Genome sequencing identifies a basis for everolimus sensitivity Science 338 2012 221
25. L. Makowski, and D.N. Hayes Role of LKB1 in lung cancer development Br J Cancer 99 2008 683 688
26. H. Ji, M.R. Ramsey, and D.N. Hayes et al. LKB1 modulates lung cancer differentiation and metastasis Nature 448 2007 807 810
27. C.M. Contreras, E.A. Akbay, and T.D. Gallardo et al. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy Dis Model Mech 3 2010 181 193
28. M. Mohseni, and B.H. Park PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001 J Clin Invest 120 2010 2655 2658